Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock Analysis

Mineralys Therapeutics, Inc. Common Stock (MLYS) is a publicly traded company in the HEALTHCARE sector. It trades at $28.85, carries a market capitalization of $2.57B. This page summarizes the public market data, fundamentals, and frequently asked questions for MLYS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $28.85
• Market Cap: $2.57B
• EPS: $-1.97
• 52-Week High: $47.65
• 52-Week Low: $12.59

Market Sentiment

Mineralys Therapeutics, Inc. Common Stock currently has a Bullish sentiment score of 0.31.

About Mineralys Therapeutics, Inc. Common Stock

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, dedicated to developing innovative therapies for hypertension and related cardiovascular conditions. The company boasts a strong pipeline of drug candidates designed to address significant unmet medical needs in the cardiovascular sector. With a strategic focus on advancing patient care and improving treatment outcomes, Mineralys is well-positioned to become a key player in redefi...

GNG Research Analysis

GNG Research scores Mineralys Therapeutics, Inc. Common Stock (MLYS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MLYS.

Frequently Asked Questions

Does MLYS pay dividends?

Mineralys Therapeutics, Inc. Common Stock (MLYS) does not currently pay a regular dividend.

What is MLYS's market cap?

Mineralys Therapeutics, Inc. Common Stock (MLYS) has a market capitalization of $2.57B with a current stock price of $28.85.